SIRT3通过去乙酰化YME1L1诱导乳腺癌内分泌治疗耐药的作用机制研究

董涧桥; 李坤艳; 李菁; 王斌; 王艳红; 贾红燕

doi:10.19401/j.cnki.1007-3639.2024.06.002

您当前的位置：

首页 >

文章列表页 >

SIRT3通过去乙酰化YME1L1诱导乳腺癌内分泌治疗耐药的作用机制研究

论著 | 更新时间：2025-12-31

- SIRT3通过去乙酰化YME1L1诱导乳腺癌内分泌治疗耐药的作用机制研究
- A study on mechanism of SIRT3 inducing endocrine drug resistance in breast cancer via deacetylating YME1L1
- 中国癌症杂志 2024年34卷第6期页码：537-547
- 作者机构：
  
  1. 山西医科大学，山西太原 030000
  2. 山西医科大学第一医院乳腺科，山西太原 030000
  3. 山西医科大学基础学院，山西太原 030000
- 作者简介：
  
  [ "董涧桥（ORCID：0009-0006-3358-741X），硕士研究生在读。" ]
  贾红燕（ORCID：0000-0001-5631-498X），教授，博士研究生导师，E-mail: swallow_jhy@163.com。
- 基金信息：
  
  山西省自然科学基金(201901D111347)
- DOI：10.19401/j.cnki.1007-3639.2024.06.002
  中图分类号： R737.9
- 收稿：2024-03-07，
  
  修回：2024-06-07，
  
  纸质出版：2024-06-30
- 稿件说明：
移动端阅览
董涧桥, 李坤艳, 李菁, 等. SIRT3通过去乙酰化YME1L1诱导乳腺癌内分泌治疗耐药的作用机制研究[J]. 中国癌症杂志, 2024,34(6):537-547.

Jianqiao DONG, Kunyan LI, Jing LI, et al. A study on mechanism of SIRT3 inducing endocrine drug resistance in breast cancer via deacetylating YME1L1[J]. China Oncology, 2024, 34(6): 537-547.
董涧桥, 李坤艳, 李菁, 等. SIRT3通过去乙酰化YME1L1诱导乳腺癌内分泌治疗耐药的作用机制研究[J]. 中国癌症杂志, 2024,34(6):537-547. DOI： 10.19401/j.cnki.1007-3639.2024.06.002.

Jianqiao DONG, Kunyan LI, Jing LI, et al. A study on mechanism of SIRT3 inducing endocrine drug resistance in breast cancer via deacetylating YME1L1[J]. China Oncology, 2024, 34(6): 537-547. DOI： 10.19401/j.cnki.1007-3639.2024.06.002.

摘要

目的：

沉默调节蛋白家族（sirtuins，SIRT）是一类以烟酰胺腺嘌呤二核苷酸（NAD

）为辅酶的第Ⅲ类组蛋白去乙酰化酶。YME1样三磷酸腺苷酶（YME1 like 1 ATPase，YME1L1）对于维持线粒体形态、功能和可塑性至关重要。视神经萎缩相关蛋白 1（optic atrophy 1，OPA1）主要介导线粒体融合。本研究拟探索乳腺癌内分泌治疗耐药中SIRT3的表达变化， SIRT3与YME1L1、OPA1之间的关系及在乳腺癌内分泌治疗耐药中的作用机制。

方法：

使用4-羟基他莫昔芬（4-hydroxytamoxifen）诱导耐他莫昔芬（tamoxifen，TAM）的MCF-7/TAM。采用细胞计数试剂盒（cell counting kit-8，CCK-8）检测细胞增殖能力，验证耐药性。采用透射电镜和免疫荧光染色（immunofluorescence staining，IF）实验观察线粒体形态。通过实时荧光定量聚合酶链反应（real-time fluorescence quantitative polymerase chain reaction，RTFQ-PCR）、蛋白质印迹法（Western blot）检测SIRT3、OPA1的基因表达和蛋白水平。采用JC-1染色检测线粒体膜电位，采用二氢乙啶（dihydroethidium，DHE）染色检测活性氧，验证线粒体功能。采用RNA干扰技术在耐药细胞中敲低SIRT3，采用过表达质粒在亲本细胞中过表达

SIRT

3及

YME

1基因野生型（wild type，WT）、模拟乙酰化状态突变型（mutant，MUT K237Q）、模拟去乙酰化状态突变型（MUT K237R）。采用免疫沉淀技术（immunoprecipitation assay，IP）及IF分析SIRT3与YME1L1之间的相互作用。

结果：

RTFQ-PCR及Western blot检测结果显示，SIRT3在耐药细胞中的表达显著高于亲本细胞。在亲本细胞中过表达SIRT3，乳腺癌细胞对TAM的敏感性出现下降。在耐药细胞中敲低SIRT3，耐药细胞对TAM的敏感性增强。DHE染色结果显示，在相同浓度的TAM处理下，耐药细胞中ROS水平低于亲本细胞；透射电镜及IF结果显示，相较于亲本细胞，耐药细胞的线粒体伸长；Western blot检测结果显示，耐药细胞L-OPA1蛋白表达水平高于亲本细胞。在亲本细胞中过表达SIRT3，线粒体功能增强，其形态较对照组更长；此外，L-OPA1表达上调；而在耐药细胞中敲低SIRT3后，得到相反结果。为了进一步验证SIRT3如何调控OPA1蛋白，影响线粒体的形态及功能，促进乳腺癌耐药，我们在亲本细胞中过表达

YME

1（野生型及突变型质粒），结果显示，过表达模拟去乙酰化状态的YME1L1与过表达SIRT3结果相似，过表达乙酰化状态的YME1L1得到与敲低SIRT3相似的结果。IP实验证实，SIRT3与YME1L

1在乳腺癌细胞中存在相互作用；在SIRT3不同表达水平下，YME1L1乙酰化水平不同。IF实验显示，在MCF-7细胞中YME1L1与SIRT3存在共定位。

结论：

SIRT3在耐TAM的乳腺癌细胞中高表达。SIRT3通过去乙酰化YME1L1上调L-OPA1表达，进而促使线粒体融合并增强线粒体功能，促进乳腺癌对TAM耐药。

Abstract

Background and purpose:

Silent information regulator proteins (sirtuins

SIRT) are a class Ⅲ histone deacetylases with nicotinamide adenine dinucleotide (NAD

) as coenzyme. YME1 like 1 ATPase (YME1L1) is essential for the maintenance of mitochondrial morphology

function and plasticity. Optic atrophy 1 (OPA1) mainly mediates mitochondrial fusion. The aim of this study was to explore the expression of SIRT3 in the endocrine resistance of breast cancer

the relationship between SIRT3 and YME1L1 and OPA1

and the mechanism of SIRT3 in the endocrine resistance of breast cancer.

Methods:

4-hydroxytamoxifen was used to induce tamoxifen-resistant MCF-7/TAM cells. cell counting kit-8 (CCK-8) was used to detect cell proliferation and verify drug resistance. The mitochondrial morphology was observed by transmission electron microscopy (TEM) and immunofluorescence staining. The expressions of SIRT3 and OPA1 were detected by real-time fluorescent quantitative polymerase chain reaction (RTFQ-PCR) and Western blot. JC-1 staining was used to detect mitochondrial membrane potential

and dihydroethidium (DHE) staining was used to detect reactive oxygen species (ROS) to verify mitochondrial function. SIRT3 was knocked down in drug-resistant cells by RNA interference

and SIRT3 and YME1L1 wild type (WT)

simulated acetylation state mutant (MUT K237Q)

and simulated deacetylation state mutant (MUT K237R) were overexpressed in parental cells by overexpression plasmid. Immunoprecipitation assay (IP) and immunofluorescence (IF) were used to verify the interaction between SIRT3 and YME1L1.

Results:

RTFQ-PCR and Western blot results showed that SIRT3 gene expression and protein level was significantly higher in drug-resistant cells

than in parental cells. Overexpression of SIRT3 in parental cells decreased the sensitivity of breast cancer cells to tamoxifen. Knockdown of SIRT3 in drug-resistant cells enhanced the sensitivity of drug-resistant cells to tamoxifen. DHE staining showed that the ROS level was lower in tamoxifen resistant cells than in parental cells at the same concentration. Transmission electron microscopy and fluorescence staining showed that the mitochondria of the drug-resistant cells were elongated compared with the parental cells. Western blot results showed that the expression level of L-OPA1 protein was higher in drug-resistant cells than in parental cells. Overexpression of SIRT3 in the parental cells resulted in enhanced mitochondrial function and longer mitochondrial morphology compared with the control cells. Western blot showed that the expression of L-OPA1 was upregulated. When SIRT3 was knocked down in drug-resistant cells

the opposite result was obtained. We further verified how SIRT3 regulated OPA1 protein

affected the morphology and function of mitochondria

and promoted drug resistance of breast cancer. Overexpression of YME1L1 (wild-type and mutant plasmids) in parental cells showed that overexpression of YME1L1 in the simulated deacetylation state resulted in similar results as overexpression of SIRT3

and overexpression of YME1L1 in the acetylated state resulted in similar results as knockdown of SIRT3. IP assay confirmed the interaction between SIRT3 and YME1L1 in breast cancer cells. The acetylation level of YME1L1 was different at different SIRT3 expression levels. IF assay showed that YME1L1 was co-localized with SIRT3 in MCF-7 cells.

Conclusion:

SIRT3 is highly expressed in tamoxifen-resistant breast cancer cells. SIRT3 upregulates L-OPA1 expression by deacetylating YME1L1

thereby promoting mitochondrial fusion and enhancing mitochondrial function

and promotes tamoxifen resistance in breast cancer.

关键词

Keywords

references

BRAY F , LAVERSANNE M , SUNG H , et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J ] . CA A Cancer J Clin , 2024 , 74 ( 3 ): 229 - 263 .

CAO W , CHEN H D , YU Y W , et al. Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020 [J ] . Chin Med J , 2021 , 134 ( 7 ): 783 - 791 .

SIEGEL R L , GIAQUINTO A N , JEMAL A . Cancer statistics, 2024 [J ] . CA Cancer J Clin , 2024 , 74 ( 1 ): 12 - 49 .

VOUDOURI K , BERDIAKI A , TZARDI M , et al. Insulin-like growth factor and epidermal growth factor signaling in breast cancer cell growth: focus on endocrine resistant disease [J ] . Anal Cell Pathol , 2015 , 2015 : 975495 .

ZAHEDIPOUR F , JAMIALAHMADI K , KARIMI G . The role of noncoding RNAs and sirtuins in cancer drug resistance [J ] . Eur J Pharmacol , 2020 , 877 : 173094 .

LIU F , YUAN L H , LI L , et al. S-sulfhydration of SIRT3 combats BMSC senescence and ameliorates osteoporosis via stabilizing heterochromatic and mitochondrial homeostasis [J ] . Pharmacol Res , 2023 , 192 : 106788 .

ZHANG J , XIANG H G , LIU J , et al. Mitochondrial Sirtuin 3: new emerging biological function and therapeutic target [J ] . Theranostics , 2020 , 10 ( 18 ): 8315 - 8342 . DOI: 10.7150/thno.45922 http://doi.org/10.7150/thno.45922

ZHANG L , REN X C , CHENG Y , et al. Identification of Sirtuin 3, a mitochondrial protein deacetylase, as a new contributor to tamoxifen resistance in breast cancer cells [J ] . Biochem Pharmacol , 2013 , 86 ( 6 ): 726 - 733 . DOI: 10.1016/j.bcp.2013.06.032 http://doi.org/10.1016/j.bcp.2013.06.032

HUBER-KEENER K J , LIU X P , WANG Z , et al. Differential gene expression in tamoxifen-resistant breast cancer cells revealed by a new analytical model of RNA-Seq data [J ] . PLoS One , 2012 , 7 ( 7 ): e41333.

Disturbance of mitochondrial dynamics and mitophagy in sepsis-induced acute kidney injury-PubMed [Internet ] . [cited 2024 Mar 2 ] . https://pubmed.ncbi.nlm.nih.gov/31479679/ https://pubmed.ncbi.nlm.nih.gov/31479679/ https://pubmed.ncbi.nlm.nih.gov/31479679/.

BAEK M L , LEE J , PENDLETON K E , et al. Mitochondrial structure and function adaptation in residual triple negative breast cancer cells surviving chemotherapy treatment [J ] . Oncogene , 2023 , 42 ( 14 ): 1117 - 1131 . DOI: 10.1038/s41388-023-02596-8 http://doi.org/10.1038/s41388-023-02596-8

ADEBAYO M , SINGH S , SINGH A P , et al. Mitochondrial fusion and fission: the fine-tune balance for cellular homeostasis [J ] . FASEB J , 2021 , 35 ( 6 ): e21620.

RUAN Y , LI H , ZHANG K , et al. Loss of Yme1L perturbates mitochondrial dynamics [J ] . Cell Death Dis , 2013 , 4 ( 10 ): e896.

ZAMBERLAN M , BOECKX A , MULLER F , et al. Inhibition of the mitochondrial protein Opa1 curtails breast cancer growth [J ] . J Exp Clin Cancer Res , 2022 , 41 ( 1 ): 95.

HANKER A B , SUDHAN D R , ARTEAGA C L . Overcoming endocrine resistance in breast cancer [J ] . Cancer Cell , 2020 , 37 ( 4 ): 496 - 513 . DOI: S1535-6108(20)30149-5 http://doi.org/S1535-6108(20)30149-5

CARRICO C , MEYER J G , HE W J , et al. The mitochondrial acylome emerges: proteomics, regulation by sirtuins, and metabolic and disease implications [J ] . Cell Metab , 2018 , 27 ( 3 ): 497 - 512 . DOI: S1550-4131(18)30068-8 http://doi.org/S1550-4131(18)30068-8

LIU L G , LI Y , CAO D Y , et al. SIRT3 inhibits gallbladder cancer by induction of AKT-dependent ferroptosis and blockade of epithelial-mesenchymal transition [J ] . Cancer Lett , 2021 , 510 : 93 - 104 .

S O , Q Z , L L , K Z , Z L , P L , et al. The double-edged sword of SIRT3 in cancer and its therapeutic applications [J ] . Front Pharmacol , 2022 , 13 : 871560 .

KENNY T C , HART P , RAGAZZI M , et al. Selected mitochondrial DNA landscapes activate the SIRT3 axis of the UPRmt to promote metastasis [J ] . Oncogene , 2017 , 36 ( 31 ): 4393 - 4404 .

ASHRAF N , ZINO S , MACINTYRE A , et al. Altered sirtuin expression is associated with node-positive breast cancer [J ] . Br J Cancer , 2006 , 95 ( 8 ): 1056 - 1061 .

CHEN S Y , YANG X , YU M , et al. SIRT3 regulates cancer cell proliferation through deacetylation of PYCR1 in proline metabolism [J ] . Neoplasia , 2019 , 21 ( 7 ): 665 - 675 . DOI: S1476-5586(18)30666-3 http://doi.org/S1476-5586(18)30666-3

KIM H S , PATEL K , MULDOON-JACOBS K , et al. SIRT3 is a mitochondria-localized tumor suppressor required for maintenance of mitochondrial integrity and metabolism during stress [J ] . Cancer Cell , 2010 , 17 ( 1 ): 41 - 52 .

DESOUKI M M , DOUBINSKAIA I , GIUS D , et al. Decreased mitochondrial SIRT3 expression is a potential molecular biomarker associated with poor outcome in breast cancer [J ] . Hum Pathol , 2014 , 45 ( 5 ): 1071 - 1077 . DOI: 10.1016/j.humpath.2014.01.004 http://doi.org/10.1016/j.humpath.2014.01.004

FINLEY L W S , CARRACEDO A , LEE J , et al. SIRT3 opposes reprogramming of cancer cell metabolism through HIF1α destabilization [J ] . Cancer Cell , 2011 , 19 ( 3 ): 416 - 428 . DOI: 10.1016/j.ccr.2011.02.014 http://doi.org/10.1016/j.ccr.2011.02.014

ANDREWS R M , KUBACKA I , CHINNERY P F , et al. Reanalysis and revision of the Cambridge reference sequence for human mitochondrial DNA [J ] . Nat Genet , 1999 , 23 ( 2 ): 147.

OHBA Y , MACVICAR T , LANGER T . Regulation of mitochondrial plasticity by the i-AAA protease YME1L [J ] . Biol Chem , 2020 , 401 ( 6/7 ): 877 - 890 .

ANAND R , WAI T , BAKER M J , et al. The i-AAA protease YME1L and OMA1 cleave OPA1 to balance mitochondrial fusion and fission [J ] . J Cell Biol , 2014 , 204 ( 6 ): 919 - 929 . DOI: 10.1083/jcb.201308006 http://doi.org/10.1083/jcb.201308006

HERKENNE S , EK O , ZAMBERLAN M , et al. Developmental and tumor angiogenesis requires the mitochondria-shaping protein Opa1 [J ] . Cell Metab , 2020 , 31 ( 5 ): 987 - 1003 .e8. DOI: S1550-4131(20)30189-3 http://doi.org/S1550-4131(20)30189-3

浏览量

1768

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

P53蛋白过表达可预测雌激素受体阳性，早期绝经后乳腺癌对芳香化酶抑制剂治疗的敏感性

中国抗癌协会乳腺癌诊治指南与规范（2026年版）

着丝粒蛋白A驱动的染色体不稳定性与乳腺癌相关性研究的进展及展望：机制、预后及临床靶向治疗应用

中国年轻女性乳腺癌发病、死亡近30年的变迁情况及趋势研究

miR-193a-3p通过靶向TRIM14对乳腺癌干细胞迁移和侵袭的影响